Breaking News

Aldevron Expands mRNA Production Capability

Will offer mRNA cGMP production from master cell bank to drug product made possible with precision nanosystems and Cytiva.

Aldevron, a global manufacturer of DNA, RNA and proteins used in cell and gene therapies and vaccine development, is expanding its mRNA production capabilities to include lipid nanoparticle (LNP) encapsulation and aseptic fill-finish capabilities enabling mRNA cGMP manufacturing services from master cell bank through to drug product. The expansion is expected to be fully online in the second half of 2023. The new capability will support the production of therapeutic-scale clinical and commerc...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters